Lower Respiratory Tract Infections Treated with Bacampicillin: A Dose Comparison

1977 ◽  
Vol 5 (5) ◽  
pp. 313-321 ◽  
Author(s):  
J Sjövall
Keyword(s):  
Success Rate ◽  
Chronic Bronchitis ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Success Rates ◽  
Dose Comparison ◽  
Number Of Patients ◽  
Acute Exacerbations ◽  
Tract Infections

In an open multicentre study of bacampicillin (Penglobe®), a new orally well absorbed prodrug of ampicillin, 516 patients with acute exacerbations of chronic bronchitis or pneumonia were treated by a group of Belgian pneumologists or internists. Bacampicillin was given in a dosage regimen of 400 mg or 800 mg three times daily. In patients with acute exacerbations of chronic bronchitis the clinical success rate was high, over 95% in both groups. A n improvement in the sputum purulence score was seen in 93% of the patients with an initially purulent sputum and 69% had a normal mucoid sputum at follow-up. The clinical success rate in patients with pneumonia was also similar in both dosage groups with success rates over 96%. The total number of patients with adverse reactions was not more than 5·4%, of which the majority were considered mild or moderate. Each type of side-effect occurred in a frequency of 1·2% or less. There were no differences between the two dosage regimens as regards the frequency of side-effects which indicates a remarkably good tolerance of bacampicillin also with the higher dosage.

scholarly journals Review of follow-up of clinical success of implant-supported complete dental prostheses

2014 ◽  
Vol 62 (3) ◽  
pp. 261-266
Author(s):  
Gustavo Diniz GRECO ◽  
Amanda Beatriz Dahdah Aniceto de FREITAS ◽  
Cláudia Silami de MAGALHÃES ◽  
Allyson Nogueira MOREIRA
Keyword(s):  
Success Rate ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Success Rates ◽  
Oral Rehabilitation ◽  
Dental Prostheses ◽  
Feasible Alternative ◽  
Edentulous Patients ◽  
Very High

OBJECTIVE: The aim of this study was to assess the clinical success rate of implant-supported complete dental prostheses, which are being used as a feasible alternative in planning of oral rehabilitation. Over the years, the two-stage surgical protocol has increasingly been replaced by immediate loading procedures, especially in the mandibular anterior region in cases of rehabilitation of completely edentulous patients. This procedure has become feasible due to the high success rate of the technique with very satisfactory results. METHODS: By means of a literature review focused on published articles with clinical follow-up between 8 and 15 years. RESULTS: Implants placed in the mandible had higher success rates than those inserted in the maxilla. Cases with longer follow-up periods, 15 years, showed higher success rates in comparison with follow-up periods of 8 and 10 years. CONCLUSION: Success rates of implant-supported complete dental prostheses are very high.

scholarly journals Meta-analysis of Outcomes Using Ceftolozane-Tazobactam and Ceftazidime-Avibactam for Multidrug-Resistant Organism Infections

2020 ◽  
Vol 41 (S1) ◽  
pp. s316-s316
Author(s):  
Geneva Wilson ◽  
Margaret Fitzpatrick ◽  
Kyle Walding ◽  
Beverly Gonzalez ◽  
Charlesnika Evans
Keyword(s):  
Success Rate ◽  
Clinical Experience ◽  
Salvage Therapy ◽  
Clinical Success ◽  
Infection Type ◽  
Clinical Success Rate ◽  
Multidrug Resistant ◽  
Solid Organ ◽  
Success Rates ◽  
Tract Infections

Background: Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (C/A) are new β-lactam/β-lactamase combination antibiotics that were approved by the FDA in 2014 and 2015, respectively, to treat complicated intra-abdominal and urinary tract infections. They are commonly used to treat multidrug-resistant Pseudomonas aeruginosa (MDRPA) and carbapenem-resistant Enterobacteriaceae (CRE) infections at any site. Both medications are also often used as salvage therapy when empiric therapy has failed or when the infectious organism tests resistant to all other available antibiotics. The purpose of this review is to present the clinical experience and reported clinical success rates of C/T and C/A. Methods: PubMed, EMBASE, and Google Scholar were searched from January 1, 2013, through October 1, 2019, for publications detailing clinical experience with C/T and C/A in patients with CRE and MDRPA infections. Included study designs were extended cases series and clinical observational studies. Information on infection type, bacterial agent, salvage therapy uses, clinical success, and resistance development during treatment were abstracted. Meta-regression analysis was used to determine the pooled effectiveness of C/T and C/A among included studies. Results: The literature search returned 1,645 publications. After exclusion criteria were applied, 16 publications representing 769 patients were retained. The study population was mostly male (pooled average, 62%). The major comorbidities represented in the pooled population were solid organ transplantation (20.0%), kidney disease (19.5%), cardiovascular disease (15.3%), and diabetes (15.3%). Pneumonia was the predominant infection type (41.4%) and MDRPA was the pathogen most frequently evaluated (57.7%). The pooled clinical success rate was 70.2% (95% CI, 64.5%–75.3%). Also, 10 studies explicitly evaluated C/A or C/T as salvage therapy. The pooled clinical success rate for salvage therapy studies was 75.2% (95% CI, 69.7%–80.0%). Development of resistance to C/T or C/A during or after treatment was reported for 2.0% of the population. Conclusion: Overall, these medications have a high clinical success rate in patients with severe and complicated infections and limited treatment options. Pooled clinical success rates were high (70.2%) and the medications were particularly effective as salvage therapy. Resistance rates were low, although this could have been biased by the small percentage of studies that reported on this outcome. More longitudinal studies comparing the effectiveness of C/T and C/A against other antibiotic regimens are needed.Funding: NoneDisclosures: None

Ferric sulfate as pulpotomy agent in primary teeth: twenty month clinical follow-up

2000 ◽  
Vol 24 (4) ◽  
pp. 269-272 ◽  
Author(s):  
Hamijeta Ibricevic ◽  
Qumasha Al-Jame
Keyword(s):  
Success Rate ◽  
Primary Teeth ◽  
Root Resorption ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Ferric Sulfate ◽  
Primary Molar ◽  
Molar Teeth ◽  
The Moment

Seventy primary molar teeth, carious exposed, symptom free, without any sign of root resorption in children aged from 3 to 6 years (main age 4.3yr) were treated with conventional pulpotomy procedures. Ferric sulfate 15.5% solution (applied for 15 second for 35 teeth) and formocresol solution (five minute procedure of Buckley's formula for next 35 teeth) have been used as pulpotomy agents. In both groups, pulp stumps were covered with zinc-oxide eugenol paste. Permanent restorations were stainless steel crowns. Clinical check up was every three-months and radiographic follow-up time was six and twenty months after treatment. Our results within this period revealed 100% clinical success rate in both groups. Radiographic success rate was in both groups 97.2%, while in 2.8% cases has shown internal root resorption. On the basis of these results, we can recommend ferric sulfate as a pulpotomy agent in primary teeth in substitution for formocresol at the moment.

scholarly journals Long-Term Management of Recurrent Cholecystitis after Initial Conservative Treatment: Endoscopic Transpapillary Gallbladder Stenting

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Hideki Kamada ◽  
Hideki Kobara ◽  
Naohito Uchida ◽  
Kiyohito Kato ◽  
Takayuki Fujimori ◽  
...  
Keyword(s):  
High Risk ◽  
Acute Cholecystitis ◽  
Success Rate ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Technical Success ◽  
Technical Success Rate ◽  
High Risk Patients ◽  
Risk Patients

Background. Endoscopic transpapillary gallbladder stenting (ETGBS) is an effective procedure for treating high-risk patients with acute cholecystitis and severe comorbidities. However, the efficacy of ETGBS for recurrent cholecystitis (RC) remains unclear. This study aimed to explore its efficacy in patients with RC for whom cholecystectomy is contraindicated because of its high surgical risk.Methods. Data on 19 high-risk patients who had undergone ETGBS for RC after initial conservative therapy in our institution between June 2006 and May 2012 were retrospectively examined. The primary outcome was the clinical success rate, which was defined as no recurrences of acute cholecystitis after ETGBS until death or the end of the follow-up period. Secondary outcomes were technical success rate and adverse events (AEs).Results. The clinical success rate of ETGBS was 100%, the technical success rate 94.7%, and AE rate 5%: one patient developed procedure-related mild acute pancreatitis. The clinical courses of all patients were as follows: four died of nonbiliary disease, and the remaining 15 were subsequently treated conservatively. The median duration of follow-up was 14.95 months (range 3–42 months).Conclusions. ETGBS is an effective alternative for managing RC in high-risk patients with severe comorbidities.

One-year results of gastric peroral endoscopic myotomy for refractory gastroparesis: a French multicenter study

Endoscopy ◽  
2020 ◽  
Author(s):  
Olivier Ragi ◽  
Jérémie Jacques ◽  
Julien Branche ◽  
Sarah Leblanc ◽  
Geoffroy Vanbiervliet ◽  
...  
Keyword(s):  
Success Rate ◽  
Multicenter Study ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Peroral Endoscopic Myotomy ◽  
Gastric Retention ◽  
Endoscopic Myotomy ◽  
Cardinal Symptom

Abstract Background: Data on the long-term outcomes of gastric peroral endoscopic myotomy (G-POEM) for refractory gastroparesis are lacking. We report the results of a large multicenter long-term follow-up study of G-POEM for refractory gastroparesis. Methods: This was a retrospective multicenter study of all G-POEM operations performed in seven expert French centers for refractory gastroparesis with at least 1 year of follow-up. The primary endpoint was the 1-year clinical success rate, defined as at least a 1-point improvement in the Gastroparesis Cardinal Symptom Index (GCSI). Results: 76 patients were included (60.5 % women; age 56 years). The median symptom duration was 48 months. The median gastric retention at 4 hours (H4) before G-POEM was 45 % (interquartile range [IQR] 29 % – 67 %). The median GCSI before G-POEM was 3.6 (IQR 2.8 – 4.0). Clinical success was achieved in 65.8 % of the patients at 1 year, with a median rate of reduction in the GCSI score of 41 %. In logistic regression analysis, only a high preoperative GCSI satiety subscale score was predictive of clinical success (odds ratio [OR] 3.41, 95 % confidence interval [CI] 1.01 – 11.54; P = 0.048), while a high rate of gastric retention at H4 was significantly associated with clinical failure (OR 0.97, 95 %CI 0.95 – 1.00; P = 0.03). Conclusions: The results confirm the efficacy of G-POEM for the treatment of refractory gastroparesis, as evidenced by a 65.8 % clinical success rate at 1 year. Although G-POEM is promising, prospective sham-controlled trials are urgently needed to confirm its efficacy and identify the patient populations who will benefit most from this procedure.

scholarly journals Feasibility of transrectal and transperineal fiducial marker placement for prostate cancer before proton therapy

2020 ◽  
Author(s):  
Kengo Ohta ◽  
Hiroyuki Ogino ◽  
Hiromitsu Iwata ◽  
Shingo Hashimoto ◽  
Yukiko Hattori ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Proton Therapy ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Fiducial Marker ◽  
Success Rates ◽  
Migration Rates ◽  
Pain Scores ◽  
Number Of Patients ◽  
Lower Pain

Abstract Background To compare the feasibility of transrectal and transperineal fiducial marker placement for prostate cancer before proton therapy. Materials and Methods From 2013 to 2015, the first 40 prostate cancer patients that were scheduled for proton therapy underwent transrectal fiducial marker placement, and the next 40 patients underwent transperineal fiducial marker placement (the first series). Technical and clinical success and pain scores were evaluated. In the second series (n = 280), the transrectal or transperineal approach was selected depending on the presence/absence of comorbidities, such as blood coagulation abnormalities. Seven patients refused to undergo the procedure. Thus, the total number of patients across both series was 353 (262 and 91 underwent the transrectal and transperineal approach, respectively). Technical and clinical success, complications, marker migration and the distance between the two markers were evaluated. Results In the first series, the technical and clinical success rates were 100% in both groups. The transrectal group exhibited lower pain scores than the transperineal group. The overall technical success rates of the transrectal and transperineal groups were 100% (262/262) and 99% (90/91), respectively (P > 0.05). The overall clinical success rate was 100% in both groups, and there were no major complications in either group. The migration rates of the two groups did not differ significantly. The mean distance between the two markers was 25.6 ± 7.1 mm (mean ± standard deviation) in the transrectal group and 31.9 ± 5.2 mm in the transperineal group (P < 0.05). Conclusion Both the transrectal and transperineal fiducial marker placement methods are feasible and safe.

scholarly journals Elective Percutaneous Coronary Interventions (PCI) in 100 Cases in a Centre Without On-site Cardiac Surgery Support

2013 ◽  
Vol 24 (1) ◽  
pp. 8-11
Author(s):  
Md Nurul Afsar Badrul ◽  
Kamal Ahmed ◽  
Sufia Rahman
Keyword(s):  
Success Rate ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Hospital Death ◽  
Percutaneous Coronary Interventions ◽  
Vessel Disease ◽  
Coronary Interventions ◽  
Percutaneous Coronary ◽  
The Mean

Since its introduction in 1977, Percutaneous Coronary  Interventions (PCI) is an important tool in the treatment of  coronary artery disease (CAD). It is a retrospective analysis  of data of 100 cases (132 vessels). The mean age was 50.9  years (range 30-70) with 90 (90%) male and 10 (10%) female.  Indication of PCI includes acute and old MI, Chronic stable  angina and unstable angina were 48 (48%), 33 (33%) and  19(19%) respectively. Procedure done in total 132 vessels  among 100 patients. most of the cases were single vessels  disease (SVD) {68 (68%} followed by double vessel disease  (DVD) {30(30%)} , triple vessel disease (TVD) {02 (02%)}  and chronic total occlusion (CTO) {02 (02%)}.Cobalt  chromium was commonly used stent (117 (88.6%) followed by  drug illuting stent (DES) 12 (9.1%) and bare metal stent  (BMS) 3 (2.3%). Among the site of the stent insertion left  anterior descending (LAD) 62 (47%), right coronary lesion  (RCA) 37 (28), left circumplex artery (LCX) 33  (25%).Maximum stent length was 35 mm, minimum 10mm.  Maximum stent diameter was 3.5 mm whereas minimum  diameter 2.5 mm. The mean pretreatment reference diameter  was 2.55 ± 0.20 mm and post treatment diameter 2.70 ± 0.45  mm. Angiographic, procedural and clinical success rate were  100%, 98% and 98% respectively. Major adverse  cardiovascular event (MACE) {periprocedural MI} occurred  in 2 (02 %) cases. Minor cardiovascular complications  revealed vascular haematoma 2 (02%), bleeding from access  site in 1 (01%), transient ventricular fibrillation (VF) in 3  (03%) cases. There was no hospital death, emergency CABG  before discharge from hospital. Angiographic, procedural and  clinical success rate were excellent with a little MACE and  event free survival within 30 days follow up. So, PCI is a safe  and effective method of myocardial revascularization  irrespective of lesion morphology and type of stents used at  immediate and 30 days follow up. DOI: http://dx.doi.org/10.3329/medtoday.v24i1.14106 Medicine TODAY Vol.24(1) 2012 pp.8-11

Azithromycin versus Pivampicillin in the Treatment of Acute Exacerbations of Chronic Bronchitis: A Single-Blind, Double-Dummy, Multicentre Study

2000 ◽  
Vol 28 (3) ◽  
pp. 101-110 ◽  
Author(s):  
P Schouenborg ◽  
N Gerdes ◽  
HH Rasmussen ◽  
N Wickers-Nielsen ◽  
E Mathiassen
Keyword(s):  
Multicentre Study ◽  
Chronic Bronchitis ◽  
Clinical Symptoms ◽  
Clinical Success ◽  
Well Being ◽  
End Of Treatment ◽  
Acute Exacerbations ◽  
Single Blind ◽  
Oral Azithromycin

This single-blind, double-dummy, multicentre study compared oral azithromycin, administered as tablets, 500 mg once daily for 3 days, versus oral pivampicillin, 700 mg twice daily for 10 days, in adults with acute exacerbations of chronic bronchitis (not needing parenteral antibiotic therapy, hospitalization or oxygen support). Clinical success (cure + improvement) rates were similar for both groups at the end of treatment (day 10; azithromycin, 124 of 133 [93%]; pivampicillin, 79 of 92 [86%]) and at follow-up (day 52; 98 of 126 [78%] versus 66 of 81 [81%]). The treatments produced similar levels of pathogen eradication at the end of treatment (49 of 54 [91%] versus 32 of 37 [86%]). Azithromycin-treated patients had significantly reduced chest discomfort at the end of treatment, and a trend towards improved lung function. The two groups were similar with respect to improvements in other clinical symptoms and patient well-being, and to the incidences of adverse events and treatment discontinuations. This oral azithromycin regime is an effective treatment for acute exacerbations of chronic bronchitis, similar in efficacy to the longer pivampicillin regime and may offer superior patient compliance.

scholarly journals Modified silicone stent for the treatment of post-surgical bronchopleural fistula: A clinical observation of 17 cases

2020 ◽  
Author(s):  
Junli Zeng ◽  
Xuemei Wu ◽  
Zhide Chen ◽  
Meihua Zhang ◽  
Mingyao Ke
Keyword(s):  
Success Rate ◽  
Clinical Success ◽  
Bronchopleural Fistula ◽  
Clinical Success Rate ◽  
Massive Hemoptysis ◽  
Left Heart Failure ◽  
Silicone Stent ◽  
Life Threatening ◽  
Granulomatous Tissue

Abstract Background: Bronchopleural fistula is a rare but life-threatening event with limited therapeutic options. We aimed to investigate the efficacy and safety of the modified silicone stent in patients with post-surgical bronchopleural fistula.Methods: Between March 2016 and April 2020, we retrospectively reviewed the records of 17 patients with bronchopleural fistula and who underwent bronchoscopic placement of the Y-shaped silicone stent. The rate of initial success, clinical success and clinical cure, and complications were analyzed.Results: Stent placement was successful in 16 patients in the first attempt (initial success rate: 94.1%). The median follow-up time was 107 (range, 5-431) days. All patients achieved amelioration of respiratory symptoms. The clinical success rate was 76.5%. Of the 14 patients with empyema, the daily drainage was progressively decreased in 11 patients, and empyema completely disappeared in six patients. Seven stents were removed during follow-up: four (26.7%) for the cure of fistula, two for severe proliferation of granulomatous tissue and one for stent dislocation. No severe adverse events (i.e. massive hemoptysis, suture dehiscence) took place. Seven patients died (due to progression of malignancy, uncontrolled infection, myocardial infarction and left heart failure).Conclusions: The modified silicone stent may be an effective and safe option for patients with post-surgical bronchopleural fistula patients in whom conventional therapy is contraindicated.

scholarly journals Endoscopic treatment of Zenkerʼs diverticulum by complete septotomy: initial experience in 19 patients

2020 ◽  
Vol 08 (07) ◽  
pp. E885-E890
Author(s):  
Charlotte Juin ◽  
Maximilien Barret ◽  
Arthur Belle ◽  
Einas Abouali ◽  
Sarah Leblanc ◽  
...  
Keyword(s):  
Success Rate ◽  
Endoscopic Treatment ◽  
Clinical Success ◽  
Muscularis Propria ◽  
Clinical Success Rate ◽  
Therapeutic Modality ◽  
Complete Regression ◽  
Muscle Sparing ◽  
Lost To Follow Up

Abstract Background and study aims Endoscopic treatment of Zenker’s Diverticulum (ZD) using a flexible endoscope and a diverticuloscope consists of myotomy of the cricopharyngeus muscle, sparing the lower part of the diverticular septum. However, recurrence occurs in up to 54 % of patients at 4 years. We assessed the feasibility and safety of a complete septotomy in endoscopic treatment of ZD. Patients and methods We conducted a retrospective analysis of a prospectively collected database at a single referral center. All consecutive patients treated by complete resection of the diverticular wall were included. The endoscopic technique used a distal attachment cap and division of the ZD septum using a Dual Knife or a Triangle Tip knife in endocut mode, until the esophageal muscularis propria was seen and no residual diverticulum remained. Symptoms were evaluated using the Augsburger questionnaire. Results Nineteen patients, 10 of whom were men with mean age 79 ± 12 years, were treated by complete septotomy for a symptomatic ZD with a median size of 2.5 cm (range 1–5 cm). The clinical success rate was 100 % and the complication rate was 10 % (one pneumonia and one atrial fibrillation). Median hospital stay was 2 days (range 1–3 days). On Day 1 esophagogram, no extraesophageal contrast leakage was seen, periesophageal CO2 was still visible in two patients, and complete ZD regression was seen in 63 % of patients. The 6-month clinical success rate was 100 %, with two patients lost to follow-up, and a median symptom score of 0 (range 0–4). After a mean ± SD follow-up of 9 ± 5 months, the clinical success rate was 94 % (16/17). Conclusion Complete endoscopic septotomy is a feasible and safe therapeutic modality in patients with symptomatic ZD that does not require use of a diverticuloscope, and with good short-term efficacy. The complete regression of the diverticulum observed on Day 1 in 63 % of patients could be a marker of long-term clinical success.

Sign in / Sign up

Export Citation Format

Share Document